Wegovy Cost 2026: Monthly Price Without Insurance
Complete breakdown of Wegovy costs in 2026 without insurance: monthly pricing by dose, annual totals, savings card eligibility, and how the compounded semaglutide pathway is regulated differently.
Written by Trimi Medical Team. Medically reviewed by Dr. Sean Arora, MD. Pricing information is updated regularly based on current market data, pharmacy surveys, and manufacturer pricing announcements.
Quick links: Semaglutide treatment, tirzepatide treatment, and best GLP-1 provider guide.
More on GLP-1 Provider Comparisons
Wegovy Pricing in 2026: The Full Picture
Wegovy, manufactured by Novo Nordisk, remains one of the most effective FDA-approved weight loss medications available in 2026. It also remains one of the most expensive. Understanding the complete cost picture, beyond just the sticker price, is essential for patients evaluating whether Wegovy fits their budget or whether another treatment pathway makes more sense.
The retail price of Wegovy without insurance hovers around $1,300 to $1,500 per month in 2026. This price applies across all dose levels of the medication, meaning you pay the same whether you are on the 0.25mg starter dose or the 2.4mg maintenance dose. This flat pricing structure means that patients in the early titration phase are paying the same amount for a fraction of the active ingredient they will eventually use at maintenance doses.
Beyond the medication cost itself, patients should account for several additional expenses that may apply depending on their healthcare pathway: provider consultation fees if not using a telehealth platform with included consultations, pharmacy dispensing fees, potential prior authorization processing costs through insurance, and follow-up visit charges. When all costs are included, the true total cost of obtaining and maintaining Wegovy treatment can exceed the retail medication price alone.
Monthly Cost by Dose Level
Wegovy follows a standard dose titration schedule, starting low and increasing gradually over approximately 16 to 20 weeks to reach the maintenance dose. Unlike many medications where the price scales with the dose, Wegovy's pricing is essentially flat, the cost per pen is the same regardless of the dose it contains.
| Dose Level | Treatment Phase | Wegovy Retail Price | Typical Duration |
|---|---|---|---|
| 0.25mg weekly | Weeks 1-4 | ~$1,350/mo | 4 weeks |
| 0.5mg weekly | Weeks 5-8 | ~$1,350/mo | 4 weeks |
| 1mg weekly | Weeks 9-12 | ~$1,350/mo | 4 weeks |
| 1.7mg weekly | Weeks 13-16 | ~$1,350/mo | 4 weeks |
| 2.4mg weekly | Maintenance | ~$1,350/mo | Ongoing |
As the table shows, Wegovy's retail price does not change as you titrate. During the first two months of treatment at the lowest doses, patients using Wegovy pay over $1,300 per month for a dose that contains a small fraction of the active ingredient they will need at maintenance. Compounded semaglutide through platforms like Trimi is billed as a flat monthly cash-pay subscription rather than per pen, and is not FDA-approved as a drug.
Annual Cost Projections
Understanding the annual cost is critical because GLP-1 weight loss treatment is typically a long-term commitment. Most patients remain on treatment for 12 months or longer, and some continue indefinitely to maintain their weight loss results. The cumulative financial impact over a year or more is substantial.
At retail pricing, a full year of Wegovy costs approximately $16,200, roughly the price of a used car, a year of in-state college tuition, or several months of mortgage payments. Over two years of treatment, that total approaches $32,400. These numbers are not sustainable for the vast majority of patients without substantial insurance support, which is why the Wegovy alternatives market has grown so rapidly.
Compounded semaglutide follows a different pricing structure entirely. Trimi's compounded semaglutide is a flat $99 per month on the annual plan, billed as a cash-pay subscription with no insurance claim to file and no prior authorization to clear. It is a distinct regulatory pathway: prepared per individual prescription by a state-licensed pharmacy, not FDA-approved as a drug, and not studied in clinical trials of its own.
Insurance Coverage Reality
The assumption that insurance will make Wegovy affordable is often incorrect. The reality of insurance coverage for GLP-1 weight loss medications in 2026 is complicated and frequently disappointing for patients who expect their plan to shoulder most of the cost.
Many employer-sponsored plans explicitly exclude anti-obesity medications from their formulary
Plans that cover Wegovy often require prior authorization, which can take weeks and may be denied
Step therapy requirements may mandate trying cheaper medications first before Wegovy is approved
High-deductible health plans mean patients pay full retail until their deductible is met
Even with coverage, specialty tier copays can be $200 to $500 per month or more
Coverage can be revoked if the insurer determines the patient does not meet ongoing criteria
Given these realities, many patients who initially pursue Wegovy through insurance end up asking their provider about compounded semaglutide after experiencing coverage denials, extended wait times for authorization, or an out-of-pocket amount that changes month to month. Compounded semaglutide is available through providers like Trimi on a flat cash-pay basis and is not FDA-approved as a drug.
Savings Programs and Coupons
Novo Nordisk and various third-party organizations offer savings programs for Wegovy, but these programs have important limitations that patients should understand before relying on them as their primary cost-reduction strategy.
The Novo Nordisk savings card, often promoted as a way to reduce Wegovy costs, typically requires that the patient have commercial insurance coverage as a prerequisite. Patients without insurance, those on Medicare or Medicaid, and those whose insurance explicitly excludes Wegovy generally cannot use the savings card. Even eligible patients face maximum benefit caps and program expiration dates that limit long-term savings. For a deeper analysis, see our Wegovy savings card comparison.
Patient assistance programs for uninsured or underinsured patients do exist, but they typically have income requirements, application processes, and limited slots. These programs can be valuable for eligible patients but are not a reliable pathway for the majority of people seeking weight loss treatment.
The Compounded Semaglutide Alternative
For patients who cannot afford Wegovy at retail pricing and do not have insurance coverage that makes it affordable, compounded semaglutide is the pathway many turn to. It is prepared by a state-licensed pharmacy against an individual prescription and is not FDA-approved as a drug. Here is what the pathway looks like in practice:
No insurance required, predictable monthly pricing
No prior authorization delays, medication ships within days of provider approval
Flexible month-to-month treatment with no long-term contracts
Provider consultations, medical oversight, and shipping included in the monthly price
Dosing flexibility allows custom titration not available with fixed pen doses
Trimi's compounded semaglutide pricing starts at $99 per month, billed as a flat cash-pay subscription with no membership fee. For patients who need long-term treatment to achieve and maintain significant weight loss, knowing exactly what the monthly bill will be is what makes staying on treatment practical.
Bottom Line
Wegovy's effectiveness is not in question, it is one of the most effective weight loss medications ever developed. The question is whether its retail price of $1,300 to $1,500 per month is sustainable for long-term treatment, and for most patients, the honest answer is no. Unless you have strong insurance coverage with low copays and no prior authorization hassles, brand-name Wegovy represents an extraordinary financial burden.
Compounded semaglutide is a separate pathway with its own tradeoffs: it is prepared by state-licensed pharmacies against an individual prescription, is not FDA-approved as a drug, and has not been studied in clinical trials of its own. Through Trimi, patients access compounded semaglutide starting at $99 per month with transparent flat pricing, quality pharmacy partnerships, and specialized weight management support. Whether that pathway is appropriate for you is a decision to make with a licensed provider.
Frequently Asked Questions
How much does Wegovy cost per month without insurance in 2026?
Wegovy's retail price without insurance is approximately $1,300 to $1,500 per month in 2026, depending on your pharmacy and location. This price is consistent across all dose levels, the 0.25mg starter dose costs the same as the 2.4mg maintenance dose. Over a year, patients paying out of pocket can expect to spend $15,600 to $18,000 for Wegovy. Compounded semaglutide through providers like Trimi is a separate cash-pay pathway; it is prepared per prescription by a state-licensed pharmacy and is not FDA-approved as a drug.
Does the Wegovy savings card really help?
Novo Nordisk offers a Wegovy savings card that can reduce costs for eligible patients, but it has significant limitations. The savings card typically requires commercial insurance coverage as a prerequisite, meaning patients without insurance cannot use it. Even with the card, copays may still be significant. The savings card also has a maximum benefit amount and expiration date. For patients without insurance or with high-deductible plans, the savings card often provides minimal relief.
Is Wegovy covered by Medicare or Medicaid?
Coverage varies. Traditional Medicare Part D plans have historically not covered weight loss medications, though the landscape has been evolving. Some Medicare Advantage plans and state Medicaid programs have begun to cover GLP-1 medications for weight management, but coverage is inconsistent and often requires prior authorization. Patients on government insurance programs should verify their specific plan's coverage. Patients who cannot get a determination often ask their provider about compounded semaglutide, which Trimi prices at a flat $99 per month cash-pay and which is not FDA-approved as a drug.
Why did Wegovy's price increase in 2026?
Pharmaceutical pricing in the United States is set by manufacturers and can increase annually. Novo Nordisk has adjusted Wegovy pricing based on market dynamics, demand, and their overall pricing strategy. While specific price increase percentages vary by year, the trend for brand-name GLP-1 medications has been upward. Patients on long-term treatment should budget for annual list-price adjustments rather than assuming today's price holds.
How does Wegovy cost compare to other brand-name GLP-1 medications?
Wegovy is among the most expensive GLP-1 medications at retail pricing. Ozempic costs approximately $900 to $1,100 per month without insurance, Mounjaro costs approximately $1,000 to $1,200 per month, and Zepbound costs approximately $1,060 per month. Wegovy's higher price reflects its specific FDA approval for chronic weight management and the premium Novo Nordisk commands for the weight-loss-specific formulation. All of these figures are retail cash-pay prices and can move with manufacturer list-price changes.
Can I afford Wegovy on a typical salary?
At $1,300 to $1,500 per month, Wegovy represents a significant financial commitment. For context, that is roughly equivalent to a car payment, and over a year it exceeds $15,000. For the median US household income of approximately $75,000, Wegovy would consume about 20 percent of pre-tax income. Patients who lack comprehensive insurance coverage often ask their provider about compounded semaglutide, which is prepared by a state-licensed pharmacy against an individual prescription and is not FDA-approved as a drug.
How do cash-pay patients access semaglutide in 2026?
Most cash-pay patients access semaglutide either through Novo Nordisk's self-pay programs for the brand-name product or through compounded semaglutide from a telehealth provider. Platforms like Trimi offer compounded semaglutide starting at $99 per month, which includes the medication, provider consultations, medical oversight, and shipping. The active ingredient is the same, the difference is the regulatory pathway and the manufacturing source: compounded preparations are made per individual prescription and are not FDA-approved as drugs.
Sources & References
- Novo Nordisk official pricing and savings card information.
- STEP 1 trial: semaglutide 2.4mg for weight management (NEJM, 2021).
- Wegovy prescribing information from the FDA.
- Centers for Medicare and Medicaid Services, prescription drug coverage information.
- FDA guidance on drug compounding.
- NIDDK overview of prescription weight loss medications.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Pricing information is based on publicly available data and may vary by pharmacy, location, and insurance status. Always verify current pricing directly with providers. Trimi offers compounded semaglutide as an alternative, readers should be aware of our perspective.